Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older

Ackerson, Bradley; Qian, Lei; Sy, Lina S.; Bruxvoort, Katia; Wu, Jun; Luo, Yi; Diaz-Decaro, John; Talarico, Carla; Tseng, Hung Fu

doi:10.1016/j.vaccine.2020.12.076

Cited by 19 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This explanation is supported by a third study that evaluated RZV completion rates in adults aged at least 50 years being members of the Kaiser Permanente healthcare plan in Southern California. 24 Completion rate in people with a first RZV dose received between January 1, 2018 and November 30, 2018 was 67.2% within 9 months (excluding the first 4 weeks), more closely reflecting results observed in the present study. The largest discrepancy in completion rates was observed when stratifying according to claim source.…”

Section: Discussionsupporting

confidence: 88%

“…16 Nevertheless, completion rates were lower in AAs compared with the overall population (66.41% vs. 70.41% at 6 months). Similar results were reported by Cubanski et al, 23 with RZV completion rates of 61% in AAs versus 74% in the overall population at 6 months and by Ackerson et al, 24 with RZV completion rates of 51.9% in AAs versus 70.7% in whites. In a recent meta-analysis, the risk of HZ was lower in AAs.…”

Section: Discussionsupporting

confidence: 86%

“…This finding is in line with results from the Kaiser Permanente study in adults aged at least 50 years: series completion rates were 56.5% versus 67.6% (P < 0.001) in people with and without Medicaid status, respectively. 24 Lower series completion rates in Medicaid versus non-Medicaid beneficiaries have been observed for multidose hepatitis A and B vaccines. 17 It was hypothesized that lower socioeconomic level, often associated with Medicaid status, may negatively impact immunization-seeking behavior.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis

Patterson¹,

Chen²,

McGuiness³

et al. 2022

Journal of the American Pharmacists Association

View full text Add to dashboard Cite

Background/Objectives: Vaccination against herpes zoster (HZ) is an effective strategy in protecting the population against consequences of varicella zoster virus reactivation. Optimal immunogenicity with recombinant zoster vaccine (RZV) relies on completion of the 2-dose series within 2-6 months from the first dose. The objectives of this study were to estimate RZV completion rates and adherence with the recommended administration schedule in the general United States population aged at least 50 years and to evaluate factors influencing completion rates. Methods: Longitudinal, open-source pharmacy and medical claims databases were analyzed for adults aged at least 50 years with a first RZV prescription filled between October 2017 and September 2019. The data were linked to Experian Marketing Services Consumer View data to obtain information regarding race. Completion rates and adherence were calculated overall and stratified according to claim source, age class, sex, and payer type. Logistic regression models were built for each subpopulation of interest to identify factors correlating with completion rates. Results: Overall, cumulative completion rates were 70.41% and 81.80% at 6 and 12 months, respectively. Median time to second dose was approximately 4 months (4.08-5.13 months) and adherence 67.62%. Completion rates were lower in the medical claims database compared with the pharmacy claims database (48.98% vs. 73.23% at 6 months). Regression models confirmed that pharmacy claim was an independent factor for higher completion rates, while African American race and Medicaid Disclosure: Brandon J. Patterson, Lisa I. Glasser, and Philip O. Buck were employees of the GSK group of companies and held shares in the GSK group of companies. Brandon J. Patterson is currently an employee of Janssen Global Services and holds shares in Janssen Global Services. Philip O. Buck is currently an employee of Moderna, Inc and holds shares in Moderna, Inc. Lisa I. Glasser is currently an employee of AstraZeneca and holds shares in AstraZeneca. Siyu Ma is a PostDoc research fellow from Tufts Medical Center and from the GSK group of companies, and declares her institution has received grant support from the GSK group of companies for the conduct of the study. Chi-Chang Chen, Catherine B. McGuiness, and Kainan Sun are employees of IQVIA, which was contracted by the GSK group of companies for the conduct of this study. Catherine B.McGuiness reports holding shares in Pfizer. The authors declare no other financial and non-financial relationships and activities. Funding: This work was supported by GlaxoSmithKline Biologicals SA (Study identifier: HO-18-19056/ VxHO-000052). GlaxoSmithKline Biologicals SA was involved in all stages of study conduct, including analysis of the data. Glax-oSmithKline Biologicals SA also covered all costs associated with the development and publication of this manuscript. Trademarks: Zostavax is a trademark of Merck Sharp & Dohme. Shingrix is a trademark owned by or licensed to the GSK group of companies. Con...

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis

Patterson¹,

Chen²,

McGuiness³

et al. 2022

Journal of the American Pharmacists Association

View full text Add to dashboard Cite

show abstract

“…Older persons suffer the most morbidity and mortality associated with COVID-19 and would highly benefit from vaccination [17] , [18] , [19] . Other vaccines have demonstrated high series completion among older adults despite high reactogenicity if the perceived severity of the vaccine-preventable disease is also high [20] . It may be helpful for health care providers to mention this lower reactogenicity profile, assess perceptions of reactogenicity, and discuss the severity of COVID-19 with older persons who are particularly concerned about side effects from mRNA-based COVID-19 vaccines.…”

Section: Discussionmentioning

confidence: 99%

Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system

Chapin-Bardales

Myers

Gee

et al. 2021

Vaccine

View full text Add to dashboard Cite

“…In the United States, few adults have received all recommended vaccines, and in National Health Interview Survey data from 2018, 24.1% of adults aged ≥50 years and 34.5% of adults aged ≥60 years had received a dose of HZ vaccine [ 18 ]. In another study at KPSC, completion of the 2-dose RZV series among those who initiated was observed to be suboptimal [ 19 ]. Interventions to increase concomitant vaccination, when recommended and when patients are eligible for multiple vaccines, may help increase adult vaccination coverage and series completion.…”

Section: Discussionmentioning

confidence: 99%

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination

Bruxvoort

Qian

et al. 2022

Open Forum Infectious Diseases

Self Cite

View full text Add to dashboard Cite

Background The 2-dose recombinant zoster vaccine (RZV) series is recommended for prevention of herpes zoster (HZ) in adults aged ≥50 years, but data are limited on the impact of concomitant administration with other vaccines on subsequent HZ risk. Methods This cohort study included Kaiser Permanente Southern California members aged ≥50 years who received 2 doses of RZV 4 weeks to ≤6 months apart during 1 April 2018–30 September 2019. RZV recipients with and without same-day concomitant vaccination for either RZV dose were followed up for incident HZ beginning 31 days after the second RZV dose until 30 September 2020. The hazard ratio (HR) for HZ comparing RZV recipients with and without concomitant vaccination was estimated using Cox proportional hazards regression, adjusting for confounders. Results RZV with and without concomitant vaccination was received by 12 898 and 28 353 individuals, respectively. HZ occurred among 41 individuals with concomitant vaccination (incidence rate, 2.2 [95% confidence interval {CI}, 1.6–3.0] per 1000 person-years) and 136 without concomitant vaccination (3.4 [95% CI, 2.9–4.0] per 1000 person-years). The adjusted HR for HZ comparing RZV recipients with and without concomitant vaccination was 0.75 (95% CI, .53–1.08). Conclusions HZ risk was not significantly different between RZV recipients with and without concomitant vaccination, supporting recommendations allowing for concomitant administration of RZV with other vaccines.

show abstract

Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older

Cited by 19 publications

References 25 publications

Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis

Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis

Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination

Contact Info

Product

Resources

About